To the full analysis
Kimberly-Clark stock: growth
KMBKimberly-Clark reported $17.22B in revenue for fiscal 2025, down 14.2% on the prior year, down 2.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
0.1%
per year from 2006 to 2025, per share 1.8%
Earnings (Annual rate)
1.6%
per year from 2006 to 2025, per share 3.3%
Free cash flow (Annual rate)
0.1%
per year from 2006 to 2025, per share 1.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −2.1% | −0.8% | 0.1% |
| Revenue per share | −1.7% | 0.1% | 1.8% |
| Earnings | −3.0% | 7.2% | 1.6% |
| Earnings per share | −2.5% | 8.1% | 3.3% |
| Free cash flow | −8.2% | 2.7% | 0.1% |
| Free cash flow per share | −7.8% | 3.7% | 1.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $16.75B | $1.5B | $1.61B |
| 2007 | $18.27B | $1.82B | $1.44B |
| 2008 | $19.42B | $1.69B | $1.61B |
| 2009 | $19.12B | $1.88B | $2.63B |
| 2010 | $19.75B | $1.84B | $1.78B |
| 2011 | $20.85B | $1.59B | $1.32B |
| 2012 | $21.06B | $1.75B | $2.2B |
| 2013 | $21.15B | $2.14B | $2.09B |
| 2014 | $19.72B | $1.53B | $1.81B |
| 2015 | $18.59B | $1.01B | $1.25B |
| 2016 | $18.2B | $2.17B | $2.46B |
| 2017 | $18.26B | $2.28B | $2.14B |
| 2018 | $18.49B | $1.41B | $2.09B |
| 2019 | $18.45B | $2.16B | $1.53B |
| 2020 | $19.14B | $2.35B | $2.51B |
| 2021 | $19.44B | $1.81B | $1.72B |
| 2022 | $20.18B | $1.93B | $1.86B |
| 2023 | $20.43B | $1.76B | $2.78B |
| 2024 | $20.06B | $2.55B | $2.51B |
| 2025 | $17.22B | $2.02B | $1.64B |
Revenue by segment
How Kimberly-Clark Corporation makes its money and how that has shifted. Names are as the company reports them.
- Diapers$6.8B39%
- Consumer tissue products$4.1B24%
- Adult care products$1.9B11%
- Away from Home Professional Products$1.8B11%
- Feminine care products$1.7B10%
- Other$893.0M5%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Diapers | $6.77B | 39.3% |
| Consumer tissue products | $4.06B | 23.6% |
| Adult care products | $1.95B | 11.3% |
| Away from Home Professional Products | $1.84B | 10.7% |
| Feminine care products | $1.71B | 9.9% |
| Other | $893M | 5.2% |
| Total revenue | $17.22B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 12 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.